

Ongoing and Planned PrEP Open Label, Demonstration and Implementation Projects, April 2019							AVAC Global Advocacy for HIV Prevention
Trial/Project	Sponsor/Funder	Type/Category	Location	Population	Design/key questions	Status	Status Details
DISCOVER	Gilead Sciences	Clinical Trial	Austria, Canada, Denmark, France, Germany, Ireland, Italy, Netherlands, Scotland, Spain, United Kingdom, USA	MSM, Transgender Women	Conducted by Gilead, the purpose of the trial is to assess whether F/TAF (trade name Descovy) is safe and effective as an oral daily HIV pre-exposure prophylaxis (PrEP) product. It is being compared with F/TDF (trade name Truvada), which is approved for use as PrEP in many countries and has already been proven safe and highly effective at reducing HIV acquisition.	Ongoing	Ongoing; started September 2016.
PrEP Impact Trial	NHS England	Implementation Project	United Kingdom	High Risk Individuals	The PrEP Impact Trial looks to answer key questions about the use of PrEP by high-risk groups in England. The trial is planned to last three years and enroll 10,000 participants. Overall, it aims to address the outstanding questions about eligibility, uptake and length of use through expanding the assessment to the scale required to obtain sufficient data.	Ongoing	Ongoing; started in September 2017. Expected completion in 2020.
PROUD (pilot trial)	MRC, Public Health England	Open label extension	United Kingdom	MSM, Transgender women	In order to determine whether the immediate inclusion of anti-retroviral pre-exposure prophylaxis (PrEP) as part of the HIV risk reduction package for men who have sex with men who are at risk of acquiring HIV is clinically effective and cost-effective, a large trial of ~5,000 MSM would need to be conducted. The purpose of the PROUD pilot is to determine the feasibility of conducting such a trial in the UK.	Completed	Completed.